18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00207298|
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : January 10, 2019
Positron emission tomography (PET) is a nuclear medicine procedure based on the measurement of positron emission from radiolabelled tracer molecules. These radiotracers allow biologic processes to be measured and whole body images to be obtained which demonstrates sites of radiotracer accumulation. The most common radiotracer in use today is 18F-fluorodeoxyglucose (18F-FDG) which is a radiolabelled sugar (glucose) molecule. Imaging with 18F-FDG PET is used to determine sites of abnormal glucose metabolism and can be used to characterize and localize many types of tumours.
Cancer treatment and outcome depend largely on the accurate diagnosis and staging of disease. There is extensive data in the literature indicating the importance of FDG-PET imaging in accurately characterizing disease, as well as determining stage and sites of recurrent disease in many cancer types. For these indications, functional imaging with PET provides unique information which is not available from standard medical imaging modalities such as ultrasound, X-ray, computerized tomography (CT) or magnetic resonance imaging (MRI).
The objectives of this study are to document the safety and efficacy of 18F-FDG produced by the British Columbia Cancer Agency (BCCA) at its Tri-University Meson Facility (TRIUMF) production facility and to evaluate FDG-PET as a diagnostic and decision making tool in the management of oncology patients in British Columbia. With a population base of over 4 million people, standardized cancer treatment protocols, and evidence based guidelines for FDG-PET imaging, the BCCA is positioned to make an important contribution to defining the role of PET in the Canadian health care system.
|Condition or disease||Intervention/treatment|
|Brain Neoplasms Lung Neoplasms Lymphoma Melanoma Colorectal Neoplasms||Procedure: Positron Emission Tomography|
|Study Type :||Observational|
|Actual Enrollment :||39242 participants|
|Official Title:||Phase III Open Label Trial for Use of [18F]-Fluoro-Deoxy-Glucose (18F-FDG) in Positron Emission Tomography Imaging in Oncology|
|Study Start Date :||June 2005|
|Actual Primary Completion Date :||August 2015|
|Actual Study Completion Date :||August 2015|
- Procedure: Positron Emission Tomography
Each patient will receive an 18F-FDG PET/CT scan
- Change in management based on PET procedure [ Time Frame: Up to 6 weeks ]
- Sensitivity of PET [ Time Frame: Up to 6 weeks ]
- Safety of 18F-FDG [ Time Frame: Up to 24 hours after completion of PET scan ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00207298
|Canada, British Columbia|
|BCCA, Vancouver Centre|
|Vancouver, British Columbia, Canada, V5Z 4E6|
|Principal Investigator:||Don C Wilson, MD||British Columbia Cancer Agency|